BPC-157 is a small peptide made up of 15 amino acids, which are the building blocks of proteins. The peptide is derived from a portion of body protection compound (BPC) that is produced naturally by cells found in the stomach . The discovery that the peptide demonstrated strong organ protective and direct cell protection lead to it being developed further . Additional studies later revealed that treating with BPC-157 results in the healing of many different tissues, including skin, muscle, tendon, ligament and bone in animal studies [3-6]. Further experiments also showed significant differences between BPC-157-treated and untreated animals and highlighted that a strong, promoting involvement of BPC in the healing process was achieved through multiple biological pathways. BPC-157-treated animals grew significantly more new blood vessels when compared to controls, which shows that the peptide positively influences the healing process by stimulating angiogenesis in damaged tissue . The peptide also stimulated higher collagen and reticulin synthesis and these compounds are required for restoring and organising the repair of wounded tissue . Experiments also showed that the immune system was modulated to reduce several inflammatory compounds, which provided a potential additional tool in wound healing and management . It is now known that BPC-157 peptide enhances the expression of the growth hormone receptor and that it achieves many of these benefits by enhancing the effect of growth hormone in a dose- and time-dependent manner. Studies also show that the effect of BPC-157 is long lasting due to the stability of the pentadecapeptide . BPC-157 will enhance the effects of human growth hormone by increasing the availability of the human growth hormone receptor. Therefore, using BPC-157 in combination with other peptides that increase the availability of human growth hormone will potentiate these effects.
The recommended dose for muscle, tendon and tissue repair, based on animal studies, is equivalent to 1.6 mcg/kg. The reported half-life of BCP-157 is around 4 hours; therefore, the peptide can be dosed daily. Both oral and subcutaneous administration of BCP-157 have benefits since the peptide is highly stable through the digestive tract. However, if buying BCP-157 for muscle and tendon repair, local subcutaneous or intramuscular injection is recommended for optimal results.
BPC-157 has been administered to patients for up to 4 weeks and was shown to be safe in clinical trials for inflammatory bowel disease (PL14736). The peptide is currently in clinical trials for the treatment of multiple sclerosis . BPC-157 peptide side effects are minimal when used at the correct dose, although headaches have been reported in a small number of individuals.
- Bodis, B., et al., Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells. Life Sci, 1997. 61(16): p. Pl 243-8.
- Bódis, B., et al., Evidence for direct cellular protective effect of PL-10 substances (synthesized parts of body protection compound, BPC) and their specificity to gastric mucosal cells. Life Sciences, 1997. 61(16): p. PL243-PL248.
- Staresinic, M., et al., Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res, 2006. 24(5): p. 1109-17.
- Sebecic, B., et al., Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone, 1999. 24(3): p. 195-202.
- Staresinic, M., et al., Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res, 2003. 21(6): p. 976-83.
- Krivic, A., et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res, 2006. 24(5): p. 982-9.
- Seiwerth, S., et al., BPC 157’s effect on healing. J Physiol Paris, 1997. 91(3-5): p. 173-8.
- Chang, C.-H., et al., Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules, 2014. 19(11): p. 19066.
- Klicek, R., et al., Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci, 2008. 108(1): p. 7-17.